FONAR Net Income Plunges 33% Amidst Go-Private Bid
Ticker: FONR · Form: 10-Q · Filed: Nov 10, 2025 · CIK: 355019
Sentiment: bearish
Topics: Medical Imaging, MRI, Going Private Transaction, Shareholder Value, Profitability Decline, Healthcare Services, Management Buyout
TL;DR
**FONR's profit cratered 33% while management tries to take it private; this smells like a lowball offer, stay away.**
AI Summary
FONAR CORP reported a consolidated net income of $2.67 million for the three months ended September 30, 2025, a significant decrease of 33.25% from $4.00 million in the same period last year. Net income attributable to FONAR also fell to $2.264 million from $3.135 million, a 27.8% decline. Total revenues increased slightly by 4.3% to $26.043 million from $24.960 million, driven by a rise in patient fee revenue to $7.572 million (up 1.13%) and product sales to $316,000 (up 163.3%). However, total costs and expenses surged by 12.26% to $22.849 million, primarily due to a 32.8% increase in selling, general and administrative expenses to $6.813 million. Income from operations consequently dropped by 30.65% to $3.194 million. A key business change is the non-binding proposal from a group led by CEO Timothy Damadian and COO Luciano Bonanni to acquire all outstanding stock, potentially taking the company private. This proposal, announced on July 7, 2025, introduces significant uncertainty regarding the company's future public status and shareholder value. Cash and cash equivalents decreased by $2.058 million to $54.276 million from $56.334 million at June 30, 2025.
Why It Matters
This filing reveals a concerning drop in profitability for FONAR, with net income down over 33% year-over-year, despite a modest revenue increase. For investors, the proposed go-private transaction led by CEO Timothy Damadian and COO Luciano Bonanni introduces significant uncertainty and potential for a liquidity event, but also raises questions about the valuation and fairness for minority shareholders, especially given the group's stated unwillingness to support alternative transactions. Employees and customers might see operational shifts if the company transitions from public to private, potentially impacting strategic direction and service offerings. In the competitive medical imaging market, a private FONAR could either gain agility or face increased pressure without public market scrutiny, affecting its ability to innovate against larger players.
Risk Assessment
Risk Level: high — The company faces high risk due to a significant 33.25% decline in consolidated net income to $2.67 million and a 30.65% drop in income from operations to $3.194 million. Furthermore, the ongoing non-binding proposal from a management-led group to take the company private, coupled with the group's stated unwillingness to support alternative transactions, creates substantial uncertainty and potential for shareholder disputes regarding valuation and fairness.
Analyst Insight
Investors should exercise extreme caution and closely monitor developments regarding the proposed go-private transaction. Given the significant decline in net income and the management-led buyout attempt, consider reducing exposure or holding off on new investments until more clarity emerges on the offer's terms and the Special Committee's negotiations.
Financial Highlights
- revenue
- $26.043M
- net Income
- $2.67M
- eps
- $0.34
- cash Position
- $54.276M
- revenue Growth
- +4.3%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Patient Fee Revenue | $7.572M | +1.13% |
| Product Sales | $316,000 | +163.3% |
Key Numbers
- $2.67M — Consolidated Net Income (Decreased 33.25% from $4.00M year-over-year)
- $26.043M — Total Revenues (Increased 4.3% from $24.960M year-over-year)
- $22.849M — Total Costs and Expenses (Increased 12.26% from $20.354M year-over-year)
- $3.194M — Income from Operations (Decreased 30.65% from $4.606M year-over-year)
- $6.813M — Selling, General and Administrative Expenses (Increased 32.8% from $5.130M year-over-year)
- $54.276M — Cash and Cash Equivalents (Decreased from $56.334M at June 30, 2025)
- 6,203,465 — Common Stock Shares Outstanding (As of November 5, 2025)
- $0.34 — Basic Net Income Per Common Share (Decreased from $0.47 year-over-year)
Key Players & Entities
- FONAR CORP (company) — registrant
- Timothy Damadian (person) — Chief Executive Officer and leader of the acquisition group
- Luciano Bonanni (person) — Chief Operating Officer and member of the acquisition group
- Health Management Corporation of America (company) — wholly-owned subsidiary of FONAR
- Marshall and Stevens, Inc. (company) — financial advisor to the Special Committee
- Meister, Seelig & Fein PPLC (company) — legal counsel to the Special Committee
- NASDAQ Stock Market (regulator) — exchange where FONAR Common Stock is listed
- SEC (regulator) — Securities and Exchange Commission
- Delaware (regulator) — state of incorporation
FAQ
What were FONAR's revenues for the quarter ended September 30, 2025?
FONAR's total revenues for the three months ended September 30, 2025, were $26.043 million, an increase from $24.960 million in the same period of 2024.
How did FONAR's net income change year-over-year?
FONAR's consolidated net income decreased by 33.25% to $2.670 million for the three months ended September 30, 2025, compared to $4.000 million in the prior year period.
Who is leading the proposal to acquire FONAR?
The non-binding proposal to acquire all outstanding stock of FONAR is led by Timothy Damadian, the Company's Chief Executive Officer, and Luciano Bonanni, the Company's Chief Operating Officer.
What is the status of the FONAR go-private transaction?
The Board of Directors has established a Special Committee of independent directors to consider the proposal and negotiate. No definitive agreements have been executed, and there is no assurance the transaction will be completed.
What are the risks associated with the FONAR go-private proposal?
The primary risks include the uncertainty of the transaction's completion, potential for a low valuation for minority shareholders given the group's voting control, and the possibility of the company being delisted from NASDAQ.
What was FONAR's cash and cash equivalents balance at September 30, 2025?
As of September 30, 2025, FONAR's cash and cash equivalents stood at $54.276 million, a decrease from $56.334 million at June 30, 2025.
How much did FONAR's selling, general and administrative expenses increase?
Selling, general and administrative expenses for FONAR increased by 32.8% to $6.813 million for the three months ended September 30, 2025, up from $5.130 million in the same period last year.
What services does FONAR's subsidiary HMCA provide?
FONAR's wholly-owned subsidiary, Health Management Corporation of America (HMCA), provides comprehensive management services to diagnostic imaging facilities, including administration, leasing, staffing, legal, accounting, billing, and marketing strategies.
What is the ownership structure of Health Management Company of America (HDM)?
Currently, FONAR has a direct ownership interest of 70.63% in HDM, while other investors hold a 29.37% ownership interest.
Will FONAR's common stockholders need to approve the go-private transaction?
Yes, any definitive agreement and transaction will require approval by the Company's common stockholders and the filing of definitive proxy materials with the SEC.
Risk Factors
- Acquisition Proposal Uncertainty [high — legal]: A non-binding proposal from a group led by CEO Timothy Damadian and COO Luciano Bonanni to acquire all outstanding stock introduces significant uncertainty regarding the company's future public status. This uncertainty could impact stock valuation and strategic decision-making.
- SG&A Expense Increase [medium — operational]: Selling, general, and administrative expenses surged by 32.8% to $6.813 million in the three months ended September 30, 2025. This substantial increase outpaced revenue growth and contributed to a significant drop in operating income.
- Declining Profitability [high — financial]: Consolidated net income decreased by 33.25% to $2.67 million for the three months ended September 30, 2025, compared to $4.00 million in the prior year. Net income attributable to FONAR also fell by 27.8%. This decline in profitability, despite revenue growth, is a key concern.
- Competition in Diagnostic Imaging [medium — market]: The diagnostic imaging market is competitive, with technological advancements and evolving reimbursement policies. FONAR's ability to maintain market share and profitability depends on its innovation and cost management.
Industry Context
The diagnostic imaging industry is characterized by rapid technological advancements and a complex regulatory environment. Companies like FONAR compete on innovation, service quality, and cost-effectiveness. Trends include the increasing demand for MRI services, particularly in specialized applications, and the ongoing pressure on reimbursement rates from government and private payers.
Regulatory Implications
As a publicly traded company, FONAR is subject to SEC regulations and reporting requirements. The proposed acquisition could lead to delisting and changes in regulatory oversight. Additionally, healthcare industry regulations regarding patient data privacy (HIPAA) and medical device approvals remain critical compliance areas.
What Investors Should Do
- Monitor the acquisition proposal closely.
- Analyze the drivers of SG&A expense increase.
- Evaluate the sustainability of revenue growth against rising costs.
Key Dates
- 2025-07-07: Non-binding acquisition proposal announced — Introduces significant uncertainty about the company's future as a public entity and potential changes in shareholder value.
- 2025-09-30: End of Q2 Fiscal Year 2026 — Reporting period for the condensed consolidated financial statements, showing decreased net income and increased expenses.
- 2024-09-30: End of Q2 Fiscal Year 2025 — Prior year comparison period for financial results, highlighting a significant decline in net income.
Glossary
- Consolidated Net Income
- The total profit of a parent company and its subsidiaries after all expenses, taxes, and interest have been deducted. (Indicates the overall profitability of FONAR Corp and its subsidiaries. A decrease of 33.25% is a significant negative indicator.)
- Net Income Attributable to FONAR
- The portion of the consolidated net income that belongs to the shareholders of the parent company, FONAR Corp. (Shows the direct impact of the company's performance on its shareholders. A 27.8% decline highlights reduced earnings per share.)
- Selling, General and Administrative Expenses (SG&A)
- Costs incurred by a company for selling products and managing the business, excluding direct costs of production. (A substantial 32.8% increase in SG&A expenses significantly impacted profitability, driving down operating income.)
- Income from Operations
- Profit generated from a company's normal business operations before interest and taxes. (A 30.65% decrease indicates that the core business operations are becoming less profitable, largely due to rising expenses.)
- Non-binding proposal
- An offer or suggestion that is not legally enforceable and can be withdrawn or changed by either party. (The acquisition proposal from management creates uncertainty, as it is not a guaranteed transaction and could be altered or abandoned.)
Year-Over-Year Comparison
Compared to the same period last year, FONAR CORP experienced a significant decline in profitability, with consolidated net income dropping 33.25% to $2.67 million. While total revenues saw a modest increase of 4.3% to $26.043 million, this was overshadowed by a substantial 12.26% rise in total costs and expenses, particularly a 32.8% jump in SG&A. Income from operations consequently fell by 30.65%. The number of outstanding shares also decreased from 6,373,000 in the prior year to 6,203,000 as of November 5, 2025.
Filing Stats: 4,503 words · 18 min read · ~15 pages · Grade level 18.7 · Accepted 2025-11-10 12:56:59
Filing Documents
- fonar_10-q.htm (10-Q) — 919KB
- fonar_exhibit-31.htm (EX-31.1) — 23KB
- fonar_exhibit-32.htm (EX-32.1) — 9KB
- fonar_logo.jpg (GRAPHIC) — 14KB
- 0000355019-25-000064.txt ( ) — 5729KB
- fonr-20250930.xsd (EX-101.SCH) — 49KB
- fonr-20250930_cal.xml (EX-101.CAL) — 69KB
- fonr-20250930_def.xml (EX-101.DEF) — 199KB
- fonr-20250930_lab.xml (EX-101.LAB) — 350KB
- fonr-20250930_pre.xml (EX-101.PRE) — 292KB
- fonar_10-q_htm.xml (XML) — 966KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION PAGE
Condensed Consolidated Financial Statements (Unaudited)
Item 1. Condensed Consolidated Financial Statements (Unaudited) Condensed Consolidated Balance Sheets – as of September 30, 2025 and June 30, 2025 4 Condensed Consolidated Statements of Operations for the Three Months Ended September 30, 2025 and September 30, 2024 7 Condensed Consolidated Statements of Changes in Equity for the Three Months Ended September 30, 2025 and September 30, 2024 8 Condensed Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2025 and September 30, 2024 10 Notes to Condensed Consolidated Financial Statements 11
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 32
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 38
Controls and Procedures
Item 4. Controls and Procedures 38
- OTHER INFORMATION
PART II - OTHER INFORMATION 40
Legal Proceedings
Item 1. Legal Proceedings 40
Risk Factors
Item 1A. Risk Factors 40
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 43 I tem 3. Defaults Upon Senior Securities 43
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 43
Other Information
Item 5. Other Information 44
Exhibits
Item 6. Exhibits 44
Signatures
Signatures 45 Page 3 FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts and shares in thousands, except per share amounts) ASSETS September 30, 2025 (Unaudited) June 30, 2025 (Note 1) Current Assets: Cash and cash equivalents $ 54,276 $ 56,334 Short-term investments 122 120 Accounts receivable – net of allowances for credit losses of $ 260 and $ 264 at September 30, 2025 and June 30, 2025, respectively 5,146 5,305 Accounts receivable – related party 90 — Medical receivable 24,486 24,490 Management and other fees receivable – net of allowances for credit losses of $ 13,866 and $ 14,296 at September 30, 2025 and June 30, 2025, respectively 44,719 43,401 Management and other fees receivable – related medical practices – net of allowances for credit losses of $ 7,666 and $ 7,137 at September 30, 2025 and June 30, 2025, respectively 10,027 9,748 Inventories - net 2,748 2,813 Prepaid expenses and other current assets – related party 530 411 Prepaid expenses and other current assets 1,591 2,050 Total Current Assets 143,735 144,672 Accounts receivable – long term 3,471 3,550 Deferred income tax asset 6,314 6,349 Property and equipment – net 19,449 18,532 Note receivable – related party 567 555 Right-of-use asset – operating leases 36,122 35,136 Right-of-use asset – finance lease 320 377 Goodwill 4,269 4,269 Other intangible assets – net 3,251 2,992 Other assets 854 476 Total Assets $ 218,352 $ 216,908 See accompanying notes to the unaudited condensed consolidated financial Page 4 FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED) (Amounts and shares in thousands, except per share amounts) LIABILITIES AND EQUITY September 30, 2025 (Unaudited) June 30, 2025 (Note 1) Current Liabilities: Accounts payable $ 2,520 $ 1,302 Other current liabilities 5,088 6,975 Unearned revenue on s
financial statements
financial statements. Page 7 FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Amounts and shares in thousands) (UNAUDITED) For the Three Months Ended September 30, 2025 Common Stock Common Stock Outstanding (Shares) Class A Preferred Stock (Shares) Class C Common Stock (Shares) Paid-in capital in excess of par value Balance – June 30, 2025 $ 1 6,203 313 383 $ 178,757 Net Income — — — — — Distributions – Non controlling interest — — — — — Income – Non controlling interests — — — — — Balance – September 30, 2025 $ 1 6,203 313 383 $ 178,757 Accumulated Deficit Treasury Stock Treasury Stock (Shares) Non Controlling Interests Total Balance – June 30, 2025 $ ( 5,289 ) $ ( 860 ) 35 $ ( 12,504 ) $ 160,105 Net Income 2,264 — — — 2,264 Distributions – Non controlling interest — — — ( 1,380 ) ( 1,380 ) Income – Non controlling interests — — — 406 406 Balance – September 30, 2025 $ ( 3,025 ) $ ( 860 ) 35 $ ( 13,478 ) $ 161,395 See accompanying notes to the unaudited condensed consolidated financial Page 8 FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Amounts and shares in thousands) (UNAUDITED) For the Three Months Ended September 30, 2024 Common Stock Common Stock Outstanding (Shares) Class A Preferred Stock (Shares) Class C Common Stock (Shares) Paid-in capital in excess of par value Balance June 30,2024 $ 1 6,373 313 383 $ 180,608 Net Income — — — — — Purchase of Treasury Stock — — — — — Distributions Non controlling interest — — — — — Income Non controlling interests — — — — — Balance September 30, 2024 $ 1 6,373 313 383 $ 180,608 Accumulated Deficit Treasury Stock Treasury Stock (Shares) Non Controlling Interests Total Balance June 30, 2024 $ ( 13,624 ) $ ( 1,017 ) 45 $ ( 9,180 ) $ 156,788